Target type: cellularcomponent
An integrin complex that comprises one alpha5 subunit and one beta1 subunit. [PMID:12297042]
The integrin alpha5-beta1 complex is a transmembrane receptor protein that plays a crucial role in cell adhesion, migration, and signaling. It is composed of two subunits, alpha5 and beta1, both of which are type I transmembrane proteins. The extracellular domain of the alpha5 subunit binds to the Arg-Gly-Asp (RGD) sequence present in various extracellular matrix (ECM) proteins, particularly fibronectin. The beta1 subunit, on the other hand, interacts with other integrin subunits and with intracellular signaling molecules. The two subunits associate non-covalently through their transmembrane domains, forming a heterodimer. The cytoplasmic domains of both alpha5 and beta1 interact with a variety of intracellular proteins, including focal adhesion kinase (FAK), talin, and paxillin. These interactions are essential for the formation of focal adhesions, which are specialized structures that connect the ECM to the actin cytoskeleton. The integrin alpha5-beta1 complex is involved in a wide range of cellular processes, including cell spreading, migration, proliferation, and differentiation. Its dysfunction has been linked to various diseases, such as cancer metastasis, cardiovascular disease, and fibrosis.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Integrin alpha-5 | An integrin alpha-5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P08648] | Homo sapiens (human) |
| Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| bupropion | bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring. Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. | aromatic ketone; monochlorobenzenes; secondary amino compound | antidepressant; environmental contaminant; xenobiotic |
| haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
| 1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
| tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
| arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
| arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
| glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
| d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
| l 738167 | L 738167: structure in first source | ||
| cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
| l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
| cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
| arginyl-glycyl-aspartyl-phenylalanine | |||
| cyclic(arg-gly-asp-d-phe-val) | |||
| mk-0429 | |||
| mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
| tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
| bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source |